Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 87
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
An Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
18 and over
Pharmaceutical / Industry
CC-5013-MM-016
NCT00179647
Last Modified:
9/18/2008
 
First Published:
6/8/2005
2.
Phase III Randomized Study of Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 70
NCI
CALGB-100104
CALGB-100104, ECOG-CALGB-100104, NCT00114101
3.
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
65 and over
Pharmaceutical / Industry
CC-5013-MM-015
NCT00405756
4.
Maintenance Therapy Using Lenalidomide in Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 65
Other
0400401
French PHRC, NCT00430365
5.
Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
2007-000649-36
QUIREDEX, NCT00480363
Last Modified:
9/17/2008
 
First Published:
8/25/2007
6.
Phase III Randomized Study of Consolidation Therapy Comprising Bortezomib and Dexamethasone With Versus Without Lenalidomide in Patients With Symptomatic Multiple Myeloma Who Have Completed a Dexamethasone-Based Induction Regimen
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
ECOG-E1A05
E1A05, NCT00522392
7.
Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 65
Other
SHEBA-07-4918-IH-CTIL
NCT00551928
Last Modified:
9/18/2008
 
First Published:
1/17/2008
8.
Phase III Randomized Study of Melphalan, Prednisone, and Thalidomide Versus Melphalan, Prednisone, and Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Active
18 and over
NCI
ECOG-E1A06
E1A06, NCT00602641
Last Modified:
9/19/2008
 
First Published:
3/21/2008
9.
Phase III Randomized Study of Lenalidomide and Low-Dose Dexamethasone With Versus Without Bortezomib in Patients With Previously Untreated Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
SWOG-S0777
S0777, NCT00644228
10.
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Approved-not yet active
18 and over
Pharmaceutical / Industry
CC-5013-MM-020
NCT00689936
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute